- ￥300 - 1516
- Solarbio
- 北京
- IT5720
- 2025年07月22日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Toceranib
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
356068-94-5
- 规格：
100mg/50mg/25mg/10mg/5mg
| 规格： | 100mg | 产品价格： | ￥1516.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥990.0 |
| 规格： | 25mg | 产品价格： | ￥658.0 |
| 规格： | 10mg | 产品价格： | ￥450.0 |
| 规格： | 5mg | 产品价格： | ￥300.0 |
| 基本信息 | |
| CAS | No.356068-94-5 |
| 英文名称 | Toceranib |
| 分子式 | C22H25FN4O2 |
| 分子量 | 396.46 |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | Yellow to orange Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD16038046 |
| SMILES | CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O |
| InChIKey | SRSGVKWWVXWSJT-ATVHPVEESA-N |
| InChI | InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6，11-12，25H，3-4，7-10H2，1-2H3，(H，24，29)(H，26，28)/b17-12- |
| PubChem CID | 5329106 |
| 靶点 | PDGFR;VEGFR;c-Kit |
| 通路 | Angiogenesis; Protein Tyrosine Kinase/RTK |
| 背景说明 | 是一种受体酪氨酸激酶 (RTK) 抑制剂，能有效抑制PDGFR，VEGFR，Kit，具有抗肿瘤和抗血管生成活性，可用于犬肥大细胞肿瘤的研究。 |
| 生物活性 | Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor， and it potently inhibits PDGFR， VEGFR， and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR， respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity， and used in the treatment of canine mast cell tumors.[1-3] |
| In Vitro | Toceranib (SU11654) is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family， including PDGFR and Flk-1/KDR， with Kis of 5 and 6 nM， respectively[1]. To explore mechanisms of acquired Toceranib (TOC) resistance in canine MCT， three resistant sublines are generated from the Toceranib-sensitive exon 11 ITD c-kit mutant C2 cell line designated TR1， TR2， and TR3. Growth of the parental C2 cells is inhibited by Toceranib in a dose-dependent manner with an IC50 of 50>?1，000 nM). Sensitivity to three other KIT RTK inhibitors is similar to the observed resistance to Toceranib. The parental line as well as all three sublines retains sensitivity to the cytotoxic agents vinblastine (VBL) and CCNU. Following 72 hr culture in the presence of increasing concentrations of Toceranib， treatment na?ve， parental C2 cells detach from the culture flask and become rounded， shrunken， and clumped with increased exposure to Toceranib. In contrast， Toceranib-induced morphologic differences are not identified in the resistant sublines[2]. |
| 细胞实验 | Administration of Toceranib significantly decreases the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving Toceranib and cyclophosphamide (CYC) demonstrate a significant increase in serum concentrations of IFN-γ， which is inversely correlated with Treg numbers after 6 weeks of combination treatment[3]. |
| 细胞实验 | The c-kit mutant canine C2 mastocytoma cell line， derived from a spontaneously occurring cutaneous mast cell tumors (MCTs)， is used as the parental cell line. Cells are propagated in RPMI 1640 supplemented with 2 mM L-glutamine， 10% FBS， 100 g/mL Streptomycin， and 100 U/mL Penicillin in a 37°C incubator under a humidified atmosphere of 5% CO2. Toceranib-resistant C2 cells are selected by growing C2 cells in concentrations of Toceranib ranging from 0.02 uM to 0.3 uM and increasing in 0.025-0.05 uM increments. Three independent， Toceranib -resistant sublines are established over a period of 7 months[2]. |
| 动物实验 | Dogs[3] Fifteen client-owned dogs with advanced tumors are used. Dogs receive Toceranib at 2.75 mg/kg once every other day. After 2 weeks， oral cyclophosphamide (CYC) is added at 15 mg/m2 daily. Numbers of Treg and lymphocyte subsets are measured in blood by flow cytometry during the 8-week study period. Serum concentrations of IFN-γ are measured by ELISA. |
| 数据来源文献 | [1]. London CA， et al. Phase I dose-escalating study of SU11654， a small molecule receptor tyrosine kinase inhibitor， in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9(7):2755-68. [2]. Halsey CH， et al. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia?) in canine mast cell tumor. BMC Vet Res. 2014 May 6;10:105. [3]. Mitchell L， et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr;26(2):355-62. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IT5720 Toceranib 血管生成 索莱宝
￥300 - 1516
